Schizophrenia Clinical Trial
Official title:
"Is the Use of High Intensity Interval Training (HIIT) Feasible and Acceptable Amongst Inpatients With Severe Mental Illness (SMI)?" A Pilot Study
Verified date | September 2020 |
Source | King's College London |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
People experiencing severe mental illnesses (SMI), including schizophrenia, psychosis, bipolar disorder and major depressive disorder, are prone to poorer physical health and increased incidences of premature mortality when compared to the general population (De Hert et al., 2009; Hert et al., 2011; Hennekens et al., 2005; Tiihonen et al., 2009 . High-intensity-interval-training (HIIT) is a type of exercise involving alternating short bursts of high intensity exercise with recovery periods of rest/ light exercise (Weston, Wisløff & Coombes, 2014). HIIT improves physical health, quality of life and cognition in the general population and in those with physical health disorders (Gomes-Neto et al., 2017; Hwang, Wu & Chou, 2011; Wen et al., 2019). It has been proposed that HIIT may improve symptoms, physical health and time to discharge among inpatients with SMI. The research will involve three stages: 1) Focus groups, 2) A pilot study, 3) Follow-up qualitative interviews and focus groups. Firstly, a series of focus groups with inpatients with SMI, carers of individuals with SMI and clinical staff will be conducted. The focus groups will scope perceptions of attitudes, and practicalities of a pilot RCT. The information gained will be used to inform a pilot HIIT trial which will evaluate whether HIIT is acceptable and feasible amongst this population group. Each focus group will run for ≈2 hours and will involve an open discussion about the benefits and barriers of conducting HIIT exercise sessions in a population with SMI. Secondly, the HIIT pilot study will be trialed. The final protocol will be developed with feedback from the focus group but will involve an RCT where 12 weeks of HIIT will be compared to 12 weeks of treatment-as-usual (TAU). HIIT will be conducted, twice a week, in a supervised environment using a stationary bike. Inpatients with a diagnosis of SMI will be eligible to participate. Thirdly, follow-up qualitative interviews, with pilot study participants, those that withdrew and those that did not want to take part, and focus groups with clinical staff will address the acceptability and feasibility of HIIT.
Status | Completed |
Enrollment | 19 |
Est. completion date | August 30, 2021 |
Est. primary completion date | August 30, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: Stage 1 (Focus Groups): - Capacity to provide informed consent. - Aged =18 years. - Either be: 1) Inpatients at SLaM with a diagnosis of SMI (Major Depressive Disorder, Bipolar disorder, Schizophrenia Spectrum Disorders, 2) Carers providing unpaid support to someone with a SMI, 3) Clinical staff at SLaM. Stage 2 (HIIT Pilot RCT): - Inpatients at SLaM with a diagnosis of SMI. - Capacity to provide informed consent. - Aged 18 -60. - Ready to exercise according to the Physical Activity Readiness Questionnaire. Stage 3 (Follow-up): Qualitative interview: - inpatients who were eligible for stage 2. Stage 3 (Follow-up): Focus group: - staff who participated in stage 1. Exclusion Criteria: Stage 1 (Focus Groups): - Is aged <18 years old. Stage 2 (HIIT Pilot RCT) & Stage 3 qualitative interviews: - Is aged <18 years old or >60 years old. - Is pregnant. - Has an eating disorder. - Has a medical condition that impedes exercise, (as assessed via discussion with the patient's clinical team). Stage 3 focus group: - Did not complete stage one. ALL STAGES: - Is unable to provide informed consent. - Is unable to understand English. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Bethlem Royal Hospital, South London and maudsley NHS Trust | London | |
United Kingdom | Maudsley Hospital, South London and Maudsley NHS Trust | London |
Lead Sponsor | Collaborator |
---|---|
King's College London | National Institute for Health Research, United Kingdom, South London and Maudsley NHS Foundation Trust |
United Kingdom,
DE Hert M, Correll CU, Bobes J, Cetkovich-Bakmas M, Cohen D, Asai I, Detraux J, Gautam S, Möller HJ, Ndetei DM, Newcomer JW, Uwakwe R, Leucht S. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry. 2011 Feb;10(1):52-77. — View Citation
De Hert M, Dekker JM, Wood D, Kahl KG, Holt RI, Möller HJ. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry. 2009 Sep;24(6):412-24. doi: 10.1016/j.eurpsy.2009.01.005. Epub 2009 Aug 13. — View Citation
Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J. 2005 Dec;150(6):1115-21. Review. — View Citation
Leon AC, Davis LL, Kraemer HC. The role and interpretation of pilot studies in clinical research. J Psychiatr Res. 2011 May;45(5):626-9. doi: 10.1016/j.jpsychires.2010.10.008. Epub 2010 Oct 28. — View Citation
Tiihonen J, Lönnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, Haukka J. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 2009 Aug 22;374(9690):620-7. doi: 10.1016/S0140-6736(09)60742-X. — View Citation
Weston KS, Wisløff U, Coombes JS. High-intensity interval training in patients with lifestyle-induced cardiometabolic disease: a systematic review and meta-analysis. Br J Sports Med. 2014 Aug;48(16):1227-34. doi: 10.1136/bjsports-2013-092576. Epub 2013 Oct 21. Review. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Appetite cravings | Participants will be asked: 'On a scale of 0-10 how much do you feel like smoking?' (0 will indicate no craving and 10 will indicate a craving) | before and after the first HIIT session (or before and after 19 minutes of rest for the TAU arm | |
Other | Cigarette cravings | Participants will be asked: 'On a scale of 0-10 how much do you feel like eating a snack right now? And if you do feel like eating what would it be?' (0 will indicate no craving and 10 will indicate a craving) | before and after the first HIIT session (or before and after 19 minutes of rest for the TAU arm | |
Other | Change in Subjective Exercise Experiences Scale (SEES) score | This questionnaire contains 12-items subdivided into three subscales to assess immediate feelings of positive well-being, psychological distress and fatigue. Each subscale contains the scores from 4-items rated on a 7-point Likert scale. Higher scores for each subscale indicated higher perceptions of positive well-being, psychological distress and fatigue respectively. | before and after the first HIIT session (or before and after 19 minutes of rest for the TAU arm | |
Primary | Number of wards that agree to hosting the HIIT Pilot Study and number that do not agree to hosting the HIIT pilot study | as assessed via a tally of acceptances and refusals | Through study completion, an average of 1 year | |
Primary | Number of people who consent to take part | as assessed via a tally of acceptances and refusals | Through study completion, an average of 1 year | |
Primary | Average adherence to HIIT sessions and assessments | as assessed via a record of number of HIIT sessions and number of assessments attended, and number of HIIT sessions and assessments not attended | Throughout length of participation in the HIIT trial, 12 weeks | |
Primary | Number of Participants With Treatment-Related Adverse Events | as assessed via a tally of all medical effects observed and all medical effects reported by participants | Through study completion, an average of 1 year | |
Secondary | BMI | BMI will be measured according to criteria set out by the International Diabetes Federation (IDF). A BMI between 18.5 to 24.9 will be interpreted as a healthy weight. Scores between 25 and 29.9 will be interpreted as overweight and a BMI >30kg/m² will be classified as central obesity. | baseline, 6-weeks, 12-weeks | |
Secondary | Weight | Weight will be measured in Kg using household scales. The investigators will assess whether weight decreases after participation in the HIIT trial. | baseline, 6-weeks, 12-weeks | |
Secondary | Waist Circumference (WC) | WC will be measured according to criteria set out by the International Diabetes Febderation (IDF). For Europids, a WC = 94 cm and = 80 cm indicates central obesity for men and women respectively. For persons from South Asia, China and Japan the cut-offs are = 90 cm and = 80 cm for men and women respectively. | baseline, 6-weeks, 12-weeks | |
Secondary | Systolic and diastolic blood pressure | Blood pressure will be measured using a blood pressure monitor. Higher systolic and diastolic blood pressure indicates lower cardiovascular function. | baseline, 6-weeks, 12-weeks | |
Secondary | Maximal oxygen uptake (VO2max) | VO2max will be measured using the YMCA cycle ergometer test which is a graded exercise test. Higher VO2max scores indicate greater cardiorespiratory fitness. | baseline, 6-weeks, 12-weeks | |
Secondary | Gait speed | The investigators will measure time taken to walk 6 meters. Longer times indicate reduced physical fitness. | baseline, 6-weeks, 12-weeks | |
Secondary | Change in Montreal Cognitive Assessment (MoCA) score | MoCA scores range between 0 and 30. Lower scores indicate worse cognitive functioning. A score of 26 or over is considered to be normal. | baseline, 6-weeks, 12-weeks | |
Secondary | Change in global assessment of functioning scale (GAF) score | GAF scores range from 0-100. Lower scores indicate worse global functioning. A score under 50 indicates severe impairment to functioning. | baseline, 6-weeks, 12-weeks | |
Secondary | Change in Brief Psychiatric Rating Scale (BPRS) score | The BPRS measures depression, anxiety, hallucinations and unusual behaviour. 24 items are rated from 1-7. A higher score indicates more severe psychiatric symptoms. | baseline, 6-weeks, 12-weeks | |
Secondary | Change in the brief insomnia severity index (ISI) | ISI scores range from 0-28. 0-7 indicates no clinically significant insomnia, 8-14 indicates sub-threshold insomnia and 15-28 indicates clinical insomnia. | baseline, 6-weeks, 12-weeks | |
Secondary | Cigarette intake | Participants will be asked how many cigarettes they smoke on a typical day. | baseline, 6-weeks, 12-weeks | |
Secondary | Change in Depression Anxiety Stress Scale short version (DASS21) score | The DASS21 contains 7 items for depression, 7 for anxiety and 7 for stress. Each subscale is scored from 0-42. Higher scores indicate higher levels of depression, anxiety and stress. Scores of 21, 15 and 26 indicate severe depression, anxiety and stress respectively. | baseline, before and after the first HIIT session (or before and after 19 minutes of rest for the TAU arm), 6-weeks, 12-weeks | |
Secondary | Change in the Rosenberg Self-Esteem Scale (RSES) score | RSES scores range from 0-30. Lower scores indicate lower self-esteem. A score under 15 may indicate problematic low self-esteem. | baseline, 6-weeks, 12-weeks | |
Secondary | Change in the International Physical Activity Questionnaire (IPAQ) score | Participants are asked to quantify how much physical activity they have completed over the past 7 days. | baseline, 6-weeks, 12-weeks | |
Secondary | Change in the Behavioural Regulation in Exercise Questionnaire-3 (BREQ-3) score | The BREQ contains 24 items with a score ranging from 0-4 for each item. The items are grouped into 6 factors with 4 items in each factor. Scores from each factor are combined using a weighting approach. Higher, positive scores indicate greater relative autonomy; lower, negative scores indicate more controlled regulation. | baseline, 6-weeks, 12-weeks | |
Secondary | Change in the Short Warwick Edinburgh Mental Well-being Scale (WEMWBS) score | Scores range from 7 to 35 and higher scores indicate higher positive mental well-being. | baseline, 6-weeks, 12-weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |